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Methacholine-induced fall in forced vital capacity as 1 
a marker of asthma severity 
J. ABISHEGANADEN, C.-C. CHAN, C. B. E. CHEE AND Y.-T. WANG 
Department of Respiratory Medicine, Tan Tack Seng Hospital, Singapore 
The dose of methacholine causing a 20% fall in forced expiratory volume in 1 set (FEV,) from baseline (PD& has 
been used as an index of asthma severity. The aim of this study was to determine if the percentage fall in forced vital 
capacity (FVC) from baseline at the PD,, (dFVC%) is an independent marker of asthma severity. 
We first retrospectively studied the dFVC% and PD,, obtained from 149 consecutive newly diagnosed asthmatics 
with a positive methacholine-challenge test (MCT) . We then performed MCT on 20 normal subjects and 35 stable 
asthmatics. The ‘milder’ asthmatics (n=20) and ‘more severe’ asthmatics (n= 15) were on regular inhaled 
corticosteroids: 200,~g or less and 800,~g or more daily, respectively. A dosimeter technique was used, and normal 
subjects were given a cumulative dose of 24OOpg. The PD,, and dFVC% were calculated using log-linear 
interpolation of the last two points. Student’s unpaired t-tests and linear regression analyses were used for 
comparison and correlation of results. 
There was no significant correlation between dFVC% and PD,, among the 149 newly diagnosed asthmatics 
(r=O.l), or among the 35 known stable asthmatics (rx0.008). The more severe asthmatics had a larger dFVC% 
compared with the milder asthmatics (158% vs. 9.6%; P=O.O005). In addition, inhaled corticosteroid usage 
correlated better with dFVC% (r=0.56) than with PD,, (r=0.36). The normal subjects had a mean fall in FVC of 
only 4.8%. 
The percentage fall in FVC at PD,, (dFVC%) may be a useful index of asthma severity which is independent of 
PD,,. This index is potentially complementary to the PD,, in the assessment of asthma severity. 
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Introduction 
Bronchial hyperresponsiveness (BHR), measured as the 
concentration (PC,,) or dose (PDzO) of inhaled metha- 
choline or histamine needed to induce a 20% fall in forced 
expiratory volume in 1 set (FEV,) from baseline, is widely 
used as a diagnostic test for bronchial asthma as well as an 
index of asthma severity (l-3). However, the merits of BHR 
testing as an index of asthma severity have been questioned 
following several prospective studies which failed to show 
good correlation between BHR and the risk for clinical 
exacerbations (4-6). The PD,, (or PC,,) is a single point 
in the dose-response curve which reflects the airway sensi- 
tivity to methacholine (or histamine), that is the ease of 
airway narrowing. The level of maximal response, which 
reflects the propensity for airway closure, is not obtained 
during routine BHR testing. This propensity for airway 
closure may be indicative of the risk for life-threatening 
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exacerbations, and thus may be a more critically important 
index than PD,,. However, bronchoprovocation tests that 
employ high concentrations of agonist to measure the 
maximal plateau response directly are not practical 
because of the inherent risks of provoking an excessive fall 
in FEV,. 
Recently, Gibbons et al. (7) proposed a novel indirect 
method for detection of excessive bronchoconstriction in 
patients with mild, newly diagnosed asthma. They retro- 
spectively measured the maximal percentage fall in forced 
vital capacity (FVC) at PC,, (dFVC%), which reflects the 
gas trapped at that point of the dose-response curve due to 
excessive bronchoconstriction, and found that this index of 
airway closure was not related to the PC,,. However, unlike 
the PC,,, dFVC% was significantly related to the average 
number of prescriptions per month of oral corticosteroids, 
which suggested that it may be a more useful index of 
disease severity in asthma than PC,,. 
This study is done in two parts with different objectives. 
The first part was a retrospective study of newly diagnosed 
asthmatics to validate Gibbons et al.‘s results in our 
laboratory. The second part was a cross-sectional study 
of two different groups of stable asthmatics on inhaled 
corticosteroids to ascertain if dFVC% is an independent 
marker of disease severity. 
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TABLE 1. Demographic and lung function characteristics of 
the mild, newly diagnosed asthmatics 
done to determine the stability of the PD,, response and 
dFVC% over time in stable asthmatics. 
Patients (n) 
Age (years) 
Sex (M:F) 
FEV, (% pred.) 
FVC (% pred.) 
Geometric standard mean PD,, @g) 
Geometric standard mean log PD,, 
% fall in FVC (dFVC%) 
149 
32.0 f 13.0 
78:71 
89.3 f 14.0 
99.7 zk 15.4 
280.3 iz 1.7 
2.4 
13.8 f 4.8 
PART TWO 
Values are expressed as means f SD. PDZO is expressed as 
geometric mean value with SD in doubling doses. 
Methods 
PART ONE 
We retrospectively analysed the results of broncho- 
provocation testing in 578 consecutive patients referred for 
suspected asthma over a l-year period between December 
1995 and December 1996. Of these, 1491 had a positive 
methacholine challenge test, technically acceptable efforts 
for reliable FVC measurements (at least six second efforts), 
and were subsequently diagnosed to have bronchial asthma 
based on established criteria (8). None of the subjects had 
taken any form of oral or inhaler bronchodilator therapy 
for 12 h prior to methacholine challenge testing, and all had 
never been on any oral corticosteroids. The demographic 
and lung function characteristics of these mild, newly 
diagnosed asthmatics are shown in Table 1. 
In the second part of the study, we prospectively performed 
methacholine challenge testing on 35 outpatient stable 
asthmatics and 20 non-smoking, healthy subjects. Informed 
consent was obtained from all subjects before participation 
in the study. The asthmatics were divided into two groups 
based on disease severity prior to testing. Group 1 patients 
(n=20) with ‘milder’ asthma had symptoms less than twice 
per week, no nocturnal symptoms and were only on low- 
dose inhaled corticosteroid therapy (200 pg or less daily for 
6 months) for maintenance of asthma control. Group 2 
patients (n= 15) with ‘more severe’ asthma had symptoms at 
least twice per week, with nocturnal symptoms on one or 
more nights per week; and were on regular inhaled corti- 
costeroid 8OOpg or more daily for the last 6 months. All 
had a baseline FEVi greater than 60% predicted prior to 
provocation tests. 
METHACHOLINE CHALLENGE TESTING 
Repeat methacholine challenge test was done randomly 
in nine of these patients, all of whom were non-smokers 
(Table 2). The average duration between the initial and 
repeat tests was 6 months (range 1-12 months). All were on 
inhaled steroids lOO-1200,~g per day between the first and 
second tests, and there was no change in medication or 
steroid dosage between the two tests. The repeat tests’were 
The methacholine challenge tests were performed using the 
standard procedure described by Yan et al. (9). Aerosols of 
physiological saline and methacholine were generated by a 
dosimeter system (ME.FAR ‘MB3’, Bovezzo, Italy) to give 
an output of 0.15 ml min- ’ of aerosol and particle size of 
0.5-4.0 pm. The time of aerosol delivery was pre-set at 1.2 s 
and the pause time between inhalations at 6 s. Baseline 
pulmonary function was first performed, followed by five 
inhalations of saline which acted as a diluent control. This 
was followed by inhalations of two different concentrations 
(2.5 mg ml - ’ and 25 mg ml - ‘) of methacholine, to pro- 
vide cumulative doses ranging from 20 to 2400,~g. Doub- 
ling doses were given within the dose range of 20-2400,ug 
and all subjects received the same dose range. The FEV, 
TABLE 2. Clinical characteristics and bronchoprovocation testing results of the asthmatics who 
underwent repeat studies 
Patients (n) 
Mean (years) age 
Sex (M:F) 
FEV, (1) 
FVC (1) 
FEV, FVC - ’ 
GSM PD,, Ocg) 
GSM log PD,, 
dFVC% 
9 
39.7 k 16.2 
3:6 
First test 
2.48 f 0.97 
3.01 f 1.04 
0.82 f 0.12 
140.6 f 1.0 
2.11 f 0.45 
12.8 f 5.0 
< 
Second test 
2.42 zt 0.77 
3.1 & 0.93 
0.78 zk 0.10 
164.1 f 1.2 
2.17 f 0.45 
11.9 & 4.8 
P value* 
0.89 
0.85 
0.48 
0.48 
0.75 
0.66 
GSM, geometric standard mean; PD,,, dose of methacholine needed to induce a 20% fall in FEV,; 
dFVC%, percentage fall in FVC at PD,,. 
Values are expressed as mean f SD. PD,, is expressed as geometric mean value with SD in doubling 
doses. 
*Not statistically significant. 
and FVC were recorded by a pneumotachograph system 
(Sensormedics 2450, Yorba Linda, CA, U.S.A.) 1 min after 
each dose of methacholine. Spirometric measurements were 
made in accordance with the recommendations of the 
American Thoracic Society (10). The time course of the 
preceding inspiration was standardized (11) with rapid 
maximal inspiration without end-inspiratory pause, and the 
FVC manoeuvre was continued until a plateau in the forced 
expiratory volume curve was obvious by visual inspection. 
The minimum duration of the FVC manoeuvre was 6 sec. 
Methacholine challenge was stopped when either FEV, fell 
by at least 20% or more from baseline measured after saline 
inhalation, or until the maximum dose (24OOpg) of metha- 
choline was reached if the former was not achieved. The 
PD,, was obtained from the log dose-response curve by 
linear interpolation of the last two points. The percentage 
fall in FVC at the PD,, dose (dFVC%) of methacholine 
relative to the baseline FVC after saline inhalation was also 
calculated using log-linear interpolation. 
STATISTICAL ANALYSIS 
The values of FEV, and FVC were expressed as percentages 
of predicted based on data from our local population (12). 
Summary values were expressed as mean ( f SD) except for 
PD,, which was expressed as geometric standard mean 
(GSM) value with SD in doubling doses. Comparisons 
between two groups of patients were made using the 
Student’s two-tailed unpaired t-test. Correlations between 
pulmonary function measurements were made using linear 
regression analysis. A P-value of 0.05 or less was taken to 
be significant. The method of Bland and Altman (13) was 
used to assess repeatability of PD,, and dFVC%. 
Results 
PART ONE 
Bronchoprovocation results of the nine asthmatics who 
underwent repeat methacholine challenge testing showed 
that the average difference in PD,, between the two tests 
was less than one doubling dose (0.57 doubling dose) and 
was not statistically significant (t= - 0.75, P=O.48). Simi- 
larly, there was no statistically significant difference 
between dFVC% measured during the first vs. the second 
tests (t=0.46, P=O.66). The measurements of dFVC% and 
PD,, made approximately 6 months apart in these nine 
patients are presented in Fig. l(a) and (b). There was no 
significant relationship found between the difference in 
PD,, and the difference in dFVC% between the two tests 
(r=0.22, P=O.57). The coefficient of repeatability for PD,, 
and dFVC%, respectively, were 317pg methacholine and 
11% fall in FVC (13). 
The demographic characteristics and mean lung function 
data of the 149 patients are summarized in Table 1 and the 
frequency distri,bution of the dFVC% for’the same patients 
is shown in Fig. 2. The dFVC% had a normal frequency 
distribution (Kolmogorov-Smirtrov one-sample test of 
normality, P=O. 17). 
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FIG. 1. (a) Reproducibility of percentage fall in FVC 
(dFVC%) in nine asthmatics studied 6 months apart. 
Difference in dFVC% between first and second tests 
plotted against the mean of the first and second tests. 
(b) Reproducibility of PD,, in nine asthmatics studied 
6 months apart. Difference in PD,, @g) between first 
and second tests plotted against the mean of the first and 
second tests. 
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FIG. 2. Frequency distribution of percentage fall in FVC 
at PD,, (dFVC%) in newly diagnosed asthmatics. 
Figure 3 shows the plot of the dFVC% against the PD,, 
for the 149 patients. As shown in the Figure, these patients 
showed a broad range of response in the fall in FVC to 
methacholine (l-25%). There was no significant linear 
correlation between dFVC% and PD,, (r=O.l, P=O.l). 
This result is very similar to those obtained by Gibbons 
et al. (7). 
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FIG. 3. Plot of percentage fall in FVC at PD,, (dFVC%) 
vs. PD,, in newly diagnosed asthmatics (r=0.14, P=O. 10). 
PART TWO 
The patients in Group 1 had a significantly higher baseline 
FEV, (% pred.) than the patients in Group 2 (P=O.O16) 
(Table 3). Both groups of patients had similar age and sex 
ratios. Group 1 patients had a significantly higher PD,, and 
lower dFVC% than patients in Group 2 (Table 3). Overall, 
for the combined data (Groups 1 and 2), there was no 
significant correlation between dFVC% and PD,, measure- 
ments (rz0.008, P=O.97). There was no significant corre- 
lation between baseline pulmonary function (FEV,% pred.) 
and BHR (PDzO) (r=0.31, P=O.O7). Inhaled steroid usage 
correlated better with dFVC% (r=0.56, P=O.O005) than 
with PD,, (r=0.36, P=O.O3). 
The healthy, non-smoking subjects were of average age 
32.4 (>9.3) years, and consisted of nine women and 11 men. 
The average fall in FVC and FEV, were 4.8 (>3.6)% and 
7.7 (>3.5)% respectively. There was a fall in FVC of more 
than 10% in only two subjects (12.3 and 11.9%). There was 
no significant relationship between percentage fall in FEV, 
and FVC (r=0.05 , P>O.l). There was still no significant 
relationship even after removing the two subjects with 
percentage fall in FVC >lO% (r=0.3, PsO.1). The mean 
T 
15.8 
i 
Normals (n = 20) Group 1 (n = 20) Group 2 (n = 15) 
FIG. 4. Mean (SD) of percentage fall in FVC at PD,, 
(Group 1 and 2 patients) or at 2400,~g methacholine ’ 
(normal subjects). 
( f SD) values of the fall in FVC either at 24OOpg metha- 
choline (normal subjects) or at the PD,, (asthmatics in 
Group 1 and 2) are shown in Fig. 4. 
Discussion 
In asthmatics, the propensity for airway closure may be 
indicative of the risk of life-threatening exacerbations, and 
thus may be more critically important than the PD,,, which 
reflects mainly the ease of airway narrowing. Indeed, 
several prospective studies have found poor correlation 
between PD,, and the risk of disease exacerbation (4,5). 
TABLE 3. Comparison of demographic, baseline spirometry and methacholine provocation data 
between two groups of stable asthmatics 
Group 1 
(milder asthmatics) 
Group 2 
(more severe asthmatics) 
I, 
P-value 
II 20 15 - 
Age (years) 29.4 (11) 37.8 (15) >0.05 
Sex (F/M) 10110 817 - 
Inhaled steroids day- ’ @g) 170 (47) 1040 (238.4) ~0~0001 
Baseline FEV, (% pred.) 96.4 (11.7) 84.7 (15.4) 0.016 
Baseline FVC (% pred.) 102.1 (15.7) 104.9 (15.1) >0*05 
GSM PD,o olg) 466.5 (1.4) 106.2 (1.3) ,0.006 
dFVC% 9.6 (4.2) 158 (5.4) .’ 0.0005 
Values are expressed as mean (SD). PD,, is expressed as geometricstandard mean.(GSM) value with 
SD in doubling doses. ,‘i 
PD,,, dose of methacholine needed to induce a 20% fall in.,FEV,; dFVC%, maximal % fall in FVC 
at PD,,. 
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The maximal response plateau on the methacholine-FEV, 
dose-response curve reflects the extent to which the airways 
can narrow, when being exposed to high doses of inhaled 
methacholine. It is a more direct indicator of the degree of 
protection against excessive airway narrowing (14-18). 
However, it is neither safe nor easy to do in asthmatics. 
It has long been appreciated that residual volume (RV) 
increases (19-21) and vital capacity (VC) falls (22) signifi- 
cantly in asthmatics during induced bronchoconstriction. 
Indeed, hyperinflation and air trapping with increased total 
lung capacity (TLC) and RV from excessive broncho- 
constriction is a feature of severe asthma and status asth- 
maticus (23-25). However, during BHR testing, the TLC 
remains unchanged (26). In the susceptible asthmatic, the 
gas trapping induced during BHR testing should increase in 
a dose-dependent manner resulting in a dose-dependent rise 
in the RV. In practice, this should be easily measurable as a 
dose-dependent fall in the FVC (7). Moreover, the FE-V, is 
predominantly an index of large airways obstruction and is 
not dependent on the site of the flow limiting segment, 
which changes towards the periphery in the case of pressure 
loss over the peripheral airways or at low elastic recoil 
pressure. The dFVC% might be a more direct index of small 
airways obstruction or closure for low lung volumes. 
In the first part of this study, we have duplicated Gibbons 
et d’s (7) findings on the percentage fall in FVC at PD,, 
(dFVC%) in mild, newly diagnosed asthmatics. It is an 
index of gas-trapping not related to PD,,. In addition, in 
the second part of the study, we found similar findings in 
stable asthmatics on inhaled corticosteroids. We found that 
dFVC% was significantly higher in the group with more 
severe disease. Moreover, the inhaled steroid usage in stable 
asthmatics correlated better with dFVC% than with PDzo. 
The dFVC% may therefore provide information regarding 
excessive airway narrowing in stable asthmatics. This 
method of assessing propensity for airway closure, riz 
dFVC%, can be safely and conveniently measured during 
routine BHR testing in both mild, newly diagnosed 
asthmatics and stable asthmatics on inhaled steroids. This 
approach carries no additional risk over that of a routine 
bronchial challenge test and avoids the problems inherent 
in provoking an excessive fall in FEV,. 
We found that our asthmatic patients had a broad range 
of responses in their FEV, and FVC to methacholine, 
suggesting wide variability in the degree of protection 
against excessive bronchoconstriction in the asthmatic 
population. Among the 149 consecutive mild, newly 
diagnosed asthmatics, there was no significant correlation 
between the dFVC% and the PD,, (r=0.14, P=O.l). There 
was also no significant correlation between the dFVC% and 
the PD,, (u=O.O08, P=O.97) among the 35 stable asthmatics 
on inhaled corticosteroids. These findings imply that the 
ease of bronchoconstriction, as measured by PD,,, and the 
degree of gas trapping or propensity for airway closure, as 
reflected by dFVC%, might be due to different mechanisms 
(18,27,28) and may represent independent responses of the 
airways to pharmacological provocation. While the fall in 
FEV, reflects the tone in the large airways, the fall in FVC 
may be a more relevant indicator of the peripheral airway 
pathological process that leads to the asthmatic attack. 
There was a normal frequency distribution in the percent- 
age fall in FVC at the PD,, dose among the 149 consecutive 
cases, with a mean fall in FVC from baseline of 13.8 
( * 4.8)%. Our findings are very similar to that by Gibbons 
et al. (7), who documented a mean fall of 13.2 (* 55)% 
among 146 asthmatics. 
Reproducibility studies performed approximately 6 
months apart demonstrated stability of patterns of response 
of PD,, and dFVC% over time. The difference in PD,, 
responses between the first and second tests was less than 
one doubling&se of methacholine and was not statistically 
significant. 
An important new finding of this study was that the 
dFVC% was able to distinguish mild asthmatics from those 
who had more severe disease. The patients in Group 2 had 
more severe asthma as evidenced by increased symptoms, 
lower baseline FEV,, lower PD,, and higher daily inhaled 
corticosteroid requirement. They showed greater falls in 
FVC with methacholine. Moreover, inhaled corticosteroid 
usage correlated better with dFVC% (r=0.56) than with 
PD,, (r=0.36). This new finding may have potential clinical 
application as a marker to identify the stable asthmatic at 
risk for serious exacerbations. The dFVC% may be an 
indirect reflection of the severity of airway inflammation, 
and thus identify the asthmatic who would require a higher 
dose of corticosteroid therapy and closer monitoring. An 
alternative possibility is that it is also a reflection of the 
degree of overall chronic cellular and remodelling compo- 
nents, or other more permanent changes in the airways. 
Methacholine challenge testing in the normal subjects 
revealed a mean fall in FVC of only 4.8% from baseline 
after inhaling a cumulative dose of 24OOpg of metha- 
choline. This information gave us an objective estimate of 
the magnitude of fall in normal subjects using our pulmon- 
ary function testing protocol, which was important in 
deciding what was a significant fall in FVC when using the 
protocol. 
In summary, we have shown that excessive airway nar- 
rowing as measured by the fall in FVC measured at the 
PD,, dose of inhaled agonist may be measured con- 
veniently and safely during routine BHR testing in asth- 
matic patients. The dFVC% and PD,, were not correlated 
among newly diagnosed asthmatics, and also were not 
correlated in a cross-sectional study of stable mild to 
moderate asthmatics. They may represent independent 
responses of the airways to pharmacological provocation. 
We conclude that the percentage fall in FVC at PD,, 
(dFVC%) has potential as a clinically useful measurement 
in asthmatics. It showed a much stronger correlation with 
inhaled steroid usage when compared to the PD,,, and was 
able to distinguish mild from more severe disease in stable 
asthmatics. This index of propensity for airway closure 
may be a useful physiological marker in identifying the 
asthmatic at risk for serious disease. 
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